DOI: https://doi.org/10.22141/2224-0551.2.70.2016.73816

Biofilm The Formation in Respiratory Diseases. Influence of Ambroxol on Airway Biofilms (Literature Review)

Yu.V. Marushko, T.V. Hyshchak

Abstract


This article reviews the literature on the development of biofilms on airway in respiratory diseases and the impact of ambroxol on them. Since biofilm infections respond poorly to standard antibiotic therapy, their treatment is a serious challenge in the clinical practice. Ambroxol inhibits the formation and functional activity of biofilms, so expansion of the indications for its use in the clinical practice is promising.


Keywords


bacterial infections; biofilms; ambroxol

References


Barbier F., Andremont A., Wolff M., Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management // Curr. Opin. Pulm. Med. — 2013. — 19. — 216e28.

Bhardwaj A.K., Vinothkumar K., Rajpara N. Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance // Recent Pat. Antiinfect. Drug Discov. — 2013. — 8. — 68e83.

Bonnetti P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections // Investig. Med. Internatio­nal. — 1993. — 20. — 99-103.

Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease // Eur. Respir. J. — 2004. — 23. — 146e58.

Brusselle G.G., Joos G.F., Bracke K.R. New insights into the immunology of chronic obstructive pulmonary disease // Lancet. — 2011. — 378. — 1015e26.

Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M. et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study // Lancet. — 2007. — 370. — 741e5.

Cataldi M., Sblendorio V., Leo A., Piazza O. Biofilm-dependent airway infections: a role for ambroxol? // Pulm. Pharmacol. Ther. — 2014 Aug. — 28(2). — 98-108.

Chalmers J.D., Hill A.T. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis // Mol. Immunol. — 2013. — 55. — 27e34.

Chebotar I.V. et al. Antimicrobial Resistance of Bacteria in Biofilms // Clinical Microbiology and antimicrobial chemotherapy. — 2012. — ​Vol. 14. — ​Р. 51-58.

Coffin S.E., Klompas M., Classen D., Arias K.M., Podgorny K., Anderson D.J. et al. Practice recommendation of Society for Healthcare Epidemiology of America/Infectious Diseases Society of America (SHEA/IDSA): strategies to prevent ventilator-associated pneumonia in acute care hospitals // Infect. Control. Hosp. Epidemiol. — 2008. — 29. — ​S31e40.

Costerton J.M. et al. Bacteril biofilms: a common cause persistens infection // Science. — 1999. — ​Vol. 284. — ​Р. 1318-1322.

Dancer R., Sansom D.M. Regulatory T cells and COPD // Thorax. — 2013. — 68. — 1176e8.

Davies J.C., Bilton D. Bugs, biofilms, and resistance in cystic fibrosis // Respir. Care. — 2009. — 54. — 628e40.

Desrosiers M., Bendauah Z., Barbeau J. Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro // Am. J. Rhinol. — 2007. — 21. — 149-53.

Di Bonito M., Caiazzo S., Iannazzone M., Miccichи V., De Marco G., De Robertis E. et al. Prognostic differences between VAP caused by Acinetobacter baumannii and VAP caused by other microorganisms // Transl. Med. UniSa. — 2012. — 3. — 15e21.

Donlan R.M. et al. Biofilms: survival mechanisms of clynically relevant microorganism // Clin. Microbiol. Rev. — 2002. — ​Vol. 15. — ​Р. 167-193.

Eldika N., Sethi S. Role of nontypeable Haemophilus influenzae in exacerbations and progression of chronic obstructive pulmonary disease // Curr. Opin. Pulm. Med. — 2006. — 12. — 118e24.

Flemming H.C., Wingender J. The biofilm matrix // Nat. Rev. Microbiol. — 2010. — 8. — 623-33.

Foreman A., Psaltis A.J., Tan L.W. et al. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis // Am. J. Rhinol. Allergy. — 2009. — 23. — 556-61.

Gao X., Zhang Y., Lin Y., Li H., Xin Y., Zhang X., Xu Y., Shang X. Effect of ambroxol on biofilm of Haemophilus influenzae and bactericidal action // Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. — 2014 May. — 28(10). — 721-3.

Golub A.V. Bacterial Biofilms — ​a New Therapeutic Target? // Clinical microbiology and antimicrobial chemotherapy. — 2012. — ​Vol. 14, № 1. — ​Р. 23-29.

Hafez M.M., Aboulwafa M.M., Yassien M.A., Hassouna N.A. Activity of some mucolytics against bacterial adherence to mammalian cells // Appl. Biochem. Biotechnol. — 2009. — 158. — 97e112.

Hall-Stoodley L. et al. Evolving concepts in biofilm infections // Cell Microbiol. — 2009. — ​Vol. 11. — ​Р. 1034-1043.

Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases // Nat. Rev. Microbiol. — 2004 Feb. — 2(2). — 95e108.

Hшiby N., Bjarnsholt T., Givskov M., Molin S., Ciofu O. Antibiotic resistance of bacterial biofilms // Int. J. Antimicrob Agents. — 2010. — 35. — 322e32.

Høiby N., Ciofu O., Johansen H.K., Song Z.J., Moser C., Jensen P.О. et al. The clinical impact of bacterial biofilms // Int. J. Oral Sci. — 2011. — 3. — 55e65.

Jakobsen T.H. et al. Qualitative and quantitative determination of quorum sensing inhibition in vitro. Quorum sensing: methods and protocols // Methods in Molecular Biology. — 2011. — ​Vol. 692. — ​P. 253-263.

Kostakioti M., Hadjifrangiskou M., Hultgren S.J. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era // Cold Spring Harb. Perspect. Med. — 2013. — 3. — ​a010306.

Lambiase A., Rossano F., Piazza O., Del Pezzo M., Catania M.R., Tufano R. Typing of Pseudomonas aeruginosa isolated from patients with VAP in an intensive care unit // New Microbiol. — 2009. — 32. — 277e83.

Li F., Yu J., Yang H., Wan Z., Bai D. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms // Curr. Microbiol. — 2008. — 57. — 1e7.

Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. — 2012. — 380. — 2095e128.

Lu Q., Yu J., Bao L. et al. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model // Chemotherapy. — 2013. — 59 (1). — 51-6; doi: 10.1159/000351107.

Lu Q., Yu J., Yang X., Wang J., Wang L., Lin Y. et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing // Int. J. Antimicrob. Agents. — 2010. — 36. — 211e5.

Mah T.-​F.C., O’Toole G.A. Mechanisms of biofilm resistance to antimicrobial agents // Trends Microbiol. — 2001. — 9. — 34e9.

Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update // Expert Opin. Drug Metab. Toxicol. — 2008. — 4. — 1119e29.

Mannino D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity // Chest. — 2002. — 121(Suppl. 5). — 121Se6S.

Masterton R.G., Galloway A., French G., Street M., Armstrong J., Brown E. et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy // J. Antimicrob. Chemother. — 2008. — 62. — 5e34.

Matthew R. Parsek Bacterial Biofilms: An Emerging Link to Disease Pathogenesis // Annual Review of Microbiology. — 2003. — ​Vol. 57. — 677-701.

McNabe M., Tennant R., Danelishvili L., Young L., Bermudez L.E. Mycobacterium avium ssp. hominissuis biofilm is composed of distinct phenotypes and influenced by the presence of antimicrobials // Clin. Microbiol. Infect. — 2011. — 17. — 697e703.

Mirsaeidi M., Hadid W., Ericsoussi B., Rodgers D., Sadikot R.T. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis // Int. J. Infect. Dis. — 2013 Nov. — 17(11). — ​e1000e4.

Murphy T.F., Kirkham C., Sethi S., Lesse A.J. Expression of a peroxiredoxinglutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection // FEMS Immunol. Med. Microbiol. — 2005. — 44. — 81e9.

Muscedere J., Dodek P., Keenan S., Fowler R., Cook D., Heyland D. et al. Comprehensive evidence-based clinical practice guidelines for ventilatorassociated pneumonia: prevention // J. Crit. Care. — 2008. — 23. — 126e37.

Nazzari E., Torretta S., Pignataro L, Marchisio P., Esposito S. Role of biofilm in children with recurrent upper respiratory tract infections // European Journal of Clinical Microbiology & Infectious Diseases. — ​March 2015. — ​Vol. 34, Issue 3. — ​Р. 421-429.

Ndour C.T., Ahmed K., Nakagawa T., Nakano Y., Ichinose A., Tarhan G. et al. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae // Microb. Pathog. — 2001. — 30. — 121e7.

Nenke P. et al. The role of biofilm infection in urology // World Journal of Urology. — 2006. — ​Vol. 24. — ​Р. 13-20.

Nowak D., Antczak A., Krуl M. et al. Antioxidant properties of Ambroxol // Free Radic. Biol. Med. — 1994. — 16 (4). — 517-22.

O’Toole G., Kaplan H.B., Kolter R. Biofilm formation as microbial development // Annu Rev. Microbiol. — 2000. — 54. — 49e79.

Pintucci J.P., Corno S., Garotta M. Biofilms and infections of the upper respiratory tract // Eur. Rev. Med. Pharmacol. Sci. — 2010. — 14. — 683-90.

Pulcrano G., Panellis D., De Domenico G., Rossano F., Catania M.R. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm // FEMS Yeast Res. — 2012. — 12. — 430e8.

Ratjen F.A. Cystic fibrosis: pathogenesis and future treatment strategies // Respir. Care. — 2009. — 54. — 595e602.

Rene H.D., José M.S., Isela S.N., Claudio CR. Effects of ambroxol on Candida albicans growth and biofilm formation // Mycoses. — 2014 Apr. — 57(4). — 228-32.

Riise G.C., Qvarfordt I., Larsson S. et al. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro // Respiration. — 2000. — 67. — 552e8.

Rovina N., Koutsoukou A., Koulouris N.G. Inflammation and immune response in COPD: where do we stand? // Mediators Inflamm. — 2013. — 2013. — 413735.

Saafan M.E., Ibrahim W.S., Tomoum M.O. Role of adenoid biofilm in chronic otitis media with effusion in children // Eur. Arch. Otorhinolaryngol. — 2013 Sep. — 270(9). — 2417-25. doi: 10.1007/s00405-012-2259-1. Epub 2012 Nov 21.

Torretta S., Drago L., Marchisio P., Cappadona M., Ri­naldi V., Nazzari Е., Pignataro L. Recurrences in chronic tonsillitis substained by tonsillar biofilm-producing bacteria in children // Relationship with the grade of tonsillar hyperplasy. — 2014. — ​Vol. 77, Issue 2. — ​P. 200-204.

Sauer K., Camper A.K., Ehrlich G.D. et al. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm // J. Bacteriol. — 2002. — 184 (4). — 1140-54.

Saylam G., Tatar E.C., Tatar I., Ozdek A., Korkmaz H. Association of adenoid surface biofilm formation and chronic otitis media with effusion // Arch. Otolaryngol. Head Neck Surg. — 2010 Jun. — 136 (6). — 550-5. doi: 10.1001/archoto.2010.70.

Schuster M., Sexton D.J., Diggle S.P., Greenberg E.P. Acyl-homoserine lactone quorum sensing: from evolution to application // Ann. Rev. Microbiol. — 2013. — 67. — 43e63.

Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J. et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care Med. — 2007. — 176. — 356e61.

Shan K.D. et al. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli // J. Bacteriol. — 2004. — ​Vol. 186. — ​Р. 8172-8180.

Singh R. et al. Penetration of antibioties through Staphylococcus aureus and Staphylococcus epidermidis biofilms // J. Antimicrob. Chemother. — 2010. — ​Vol. 65. — ​Р. 1955-1958.

Snowden J.N., Beaver M., Smeltzer M.S., Kielian T. Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system // Infect. Immun. — 2012. — 80. — 3206e14.

Stewart P.S., Franklin M.J. Physiological hetero-geneity in biofilms // Nat. Rev. Microbiol. — 2008. — 6 (3). — 199-210.

Tetz V.V. et al. Extracellular phospholipids of isolated bacterial communities // Biofilms. — 2004. — ​Vol. 1. — ​Р. 149-155.

Tian X. Quorum sensing and bacterial social interactions in biofilms // Sensors (Basel). — 2012. — 12. — 2519e38.

Torres A., Ewig S., Lode H., Carlet J., European HAP working group. Defining, treating and preventing hospital acquired pneumonia: European perspective // Intensive Care Med. — 2009. — 35. — 9e29.

Varelogianni G., Hussain R., Strid H., Oliynyk I., Roomans G.M., Johannesson M. Effect of ambroxol on chloride transport, CFTR and ENaC in cystic fibrosis airway epithelial cells // Cell Biol. Int. — 2013 Jun. — 14. — ​http://dx.doi.org/10.1002/ cbin.

Vu B., Chen M., Crawford R.J. et al. Bacterial extracellular polysaccharides involved in biofilm formation // Molecules. — 2009. — 14. — 2535-54.

Vuong C., Voyich J.M., Fischer E.R., Braughton K.R., Whitney A.R., DeLeo F.R. et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system // Cell Microbiol. — 2004. — 6. — 269e75.

Wiener-Kronish J.P., Dorr H.I. Ventilator-associated pneumonia: problems with diagnosis and therapy // Best Pract. Res Clin. Anaesthesiol. — 2008. — 22. — 437e49.

Yung-Hua Li. Xiaolin Tian. Quorum Sensing and Bacterial Social Interactions in Biofilms // Sensors. — 2012. — 12. — 2519-38.

Zhang B., Liu Y. Prophylaxis against ventilator-induced lung injury by Ambroxol // Zhonghua Yi Xue Za Zhi. — 2000. — 80 (1). — 51-3.

Zhang Y., Fu Y., Yu J., Ai Q., Li J., Peng N., Song S., He Y., Wang Z. Synergy of ambroxol with vancomycin in elimination of cathe­ter-related Staphylococcus epidermidis biofilm in vitro and in vivo // J. Infect Chemother. — 2015 Nov. — 21 (11). — 808-15.

Zhao S.P., Guo Q.L., Wang R.K., Wang E. Oxidative and anti-oxidative effects of ambroxol on acute hydrochloric acid-induced lung injury in rats // Zhong Nan Da Xue Xue Bao Yi Xue Ban. — 2004. — 29 (5). — 586-8.

Beeh К.М. et al. Anti- inflammatory properties of ambroxol // Eur. J. Med. Res. — 2008. — 13. — 557-562.

Банадига Н.В. Вибір препарату для лікування кашлю у дітей: доцільність, ефективність, безпечність, комплаєнс // Современная педиатрия. — 2015. — 1 (65). — 44-49.




Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта